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TheFGFfamilycomprisestwenty-twostructurallyrelatedproteinswithfunctionsindevelopmentandmetabolism.TheFgf21gene
was generated early in vertebrate evolution. FGF21 acts as an endocrine regulator in lipid metabolism. Hepatic Fgf21 expression
is markedly induced in mice by fasting or a ketogenic diet. Experiments with Fgf21 transgenic mice and cultured cells indicate
that FGF21 exerts pharmacological eﬀects on glucose and lipid metabolism in hepatocytes and adipocytes via cell surface FGF
receptors. However, experiments with Fgf21 knockout mice indicate that FGF21 inhibits lipolysis in adipocytes during fasting and
attenuates torpor induced by a ketogenic diet but maybe not a physiological regulator for these hepatic functions. These ﬁndings
suggest the pharmacological eﬀects to be distinct from the physiological roles. Serum FGF21 levels are increased in patients with
metabolic diseases having insulin resistance, indicating that FGF21 is a metabolic regulator and a biomarker for these diseases.
1.Background
Prototypes of ﬁbroblast growth factors (FGFs), FGF1 and
FGF2, were originally isolated as mitogens for cultured
ﬁbroblasts from the brain and pituitary [1, 2]. The human/
mouse Fgf gene family comprises twenty-two members,
including Fgf1–Fgf23, all of which are evolutionarily related.
However, as mouse Fgf15 and human Fgf19 are ortholo-
gous, we refer to these genes as Fgf15/19 in this paper.
Human/mouse FGFs are proteins of ∼150–300 amino acids
with 13–71% identity. All FGFs with a ∼120 amino acid
conserved core region (∼30–60% identity) are signaling
molecules with diverse functions in development and
metabolism. Fgf genes are widely expressed in developing
and adult tissues [3–6].
FGFs can be classiﬁed into three types, paracrine,
intracrine, and endocrine FGFs, by their mechanisms of
action [6]. Paracrine FGFs (FGF1∼FGF10, FGF16∼FGF18,
FGF20, and FGF22) function as secreted local paracrine
signaling molecules in multiple developmental processes,
including diﬀerentiation, cell proliferation, and migration.
They mediate biological responses by binding to cell surface
tyrosine kinase FGF receptors (FGFRs) [4, 6, 7]. Intracrine
FGFs (FGF11∼FGF14) function as nonsecreted signaling
molecules. They mainly play roles in neuronal functions at
postnatal stages in an FGFR-independent manner [8–10].
Endocrine FGFs (FGF15/19, FGF21, and FGF23) mediate
biological responses as secreted proteins in an FGFR-
dependent manner. Endocrine FGFs function over long
distances in an endocrine manner and mainly play roles in
metabolism at postnatal stages [11–13].
Paracrine and intracrine FGFs have been identiﬁed in
bothinvertebratesandvertebrates.However,endocrineFGFs
have only been identiﬁed in vertebrates [6]. Endocrine FGFs
areemerginginevolution.FGF15/19andFGF23playrolesas
metabolic regulators in bile acid metabolism and phosphate
and active vitamin D metabolism, respectively [11, 13–15].
FGF21 exerts diverse pharmacological eﬀects on glucose
and lipid metabolism, ketogenesis, and growth hormone
signalinginhepatocytesinmice.However,FGF21maynotbe
a physiological regulator for these hepatic functions. FGF21
physiologically regulates lipid metabolism in adipocytes and
torpor. Serum FGF21 levels are signiﬁcantly increased in
patients with metabolic diseases having insulin resistance.
These results indicate the physiological and pathophysiologi-
calrolesofFGF21.SeveralexcellentreviewarticlesonFGF21,2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
focusing on its pharmacological eﬀects on metabolism and
therapeutic uses for metabolic diseases have been published
[16–20]. This paper concentrates on the molecular evolution
and physiological and pathophysiological roles of FGF21.
2. Identiﬁcation ofFgf21
The Fgf21 gene was originally identiﬁed in mice by the
polymerase chain reaction with the amino acid sequence
of human FGF15/19. Human Fgf21 was also identiﬁed by
homology-based searching in the human DNA database
[21]. Later, human FGF21 was found to act as a stimulator
of glucose uptake in mouse 3T3-L1 adipocytes in an assay
used to search for novel proteins with therapeutic potential
to treat diabetes [22]. Mouse Fgf21 was also identiﬁed as a
hepatic gene inducible by fasting or a ketogenic diet [23, 24].
Human FGF21 is a secreted protein of 209 amino
acids with a 29-amino-acid amino-terminal secreted signal
sequence and a ∼120-amino-acid conserved core region.
Human FGF21 is highly homologous to mouse FGF21
(∼75% identity). However, its low homology with other
human FGFs (less than 35% identity) indicates that FGF21
is structurally unique [21]. Paracrine FGFs have a heparin-
binding site, which is necessary for stable interaction with
FGFRs and heparin-like molecules [25]. However, FGF21 as
well as FGF15/19 and FGF23 lack a typical heparin-binding
site [25, 26].
3. Molecular Evolution of Fgf21
The FGF signaling system has been conserved throughout
metazoan evolution. Potential evolutionary relationships in
the Fgf family have been proposed based on results of
gene location and phylogenetic analyses. These analyses have
identiﬁed seven subfamilies: Fgf/1/2/5, Fgf3/4/6, Fgf7/10/22,
Fgf8/17/18, Fgf9/16/20, Fgf11/12/13/14,a n dFgf15/19/21/23
[4, 6]. Ascidians belong to the subphylum Urochordata,
the earliest branch in the phylum Chordata. Ancestral
genes of paracrine and intracrine Fgfs have been identi-
ﬁed in the ascidian, Ciona intestinalis [27]. However, no
ancestral gene of endocrine Fgfs has been identiﬁed in
Ciona intestinalis. The sea lampreys, Petromyzon marinus,
are cyclostomes, the most basal extant group of vertebrates
[28]. An ancestral gene of endocrine Fgfs has been identiﬁed
in the lamprey genome, and tentatively named Fgf15/19-
like (Itoh et al., unpublished observation) (Figure 1(a)).
Lamprey FGF15/19-like also lacks a typical heparin-binding
site. These results support that lamprey Fgf15/19-like is
an ancestral endocrine Fgf, which was generated from
the ancestral paracrine Fgf gene, Fgf4-like,b yl o c a lg e n e
duplication early in vertebrate evolution (Figure 1(b)). Later,
Fgf19, Fgf21,a n dFgf23 were generated from the ancestral
endocrine Fgf gene by two genome duplication events early
in vertebrate evolution [4, 6]. The evolutionary history
suggests that endocrine FGFs are vertebrate speciﬁc. As
described above, paracrine FGFs have a heparin-binding site.
ThesiteisnecessaryforthestablebindingofFGFRs/heparin-
like molecules and local signaling in a paracrine manner.
EndocrineFGFspotentiallyacquiredsystemicsignalinginan
endocrinemannerbyreducingheparin-bindingaﬃnityearly
in vertebrate evolution [6, 13, 25].
Endocrine Fgf genes have been identiﬁed in all ver-
tebrates examined, including teleosts, amphibians, reptiles,
birds, and mammals. Fgf21 has also been identiﬁed in
most vertebrates. However, Fgf21 has not been identiﬁed in
the chicken and zebra ﬁnch genomes (Ensemble Genome
Browser; Itoh et al., unpublished observation) (Figure 1(a)).
Genome sizes and gene numbers are smaller in birds than in
mammalian species. Although the evolutionary implications
of these changes remain to be understood, the reduced
genome sizes and gene numbers may have evolved in
response to the physiological demands of ﬂight [29]. Fgf21
might therefore have been lost in the bird lineage.
4.Roles ofFGF21inGlucose Metabolism
Fgf21 is expressed abundantly in the liver, and also in the
pancreas,whiteadiposetissue,muscle,andtestis[17, 21, 30].
Potential roles of FGF21 in glucose metabolism were ﬁrst
shown by experiments with cultured cells [22]. FGF21
stimulated glucose uptake in cultured mouse and human
adipocytes. Functional interplay between the FGF21 and
peroxisomeproliferation-activatedreceptorγ (PPARγ)path-
ways led to a marked stimulation of glucose transport,
suggesting a novel synergy between FGF21 and PPARγ
homeostasis [31]. In addition, Fgf21 transgenic mice were
resistant to diet-induced obesity. Serum glucose levels were
a l s or e d u c e dt on e a rn o r m a ll e v e l si nb o t hob/ob and db/db
micebytheadministrationofFGF21.Theseﬁndingsindicate
that FGF21 plays a role in glucose metabolism and has
potential therapeutic eﬀects on metabolic diseases [16–19].
To elucidate the physiological roles of FGF21, Fgf21
knockout mice have been generated. These mice had normal
food intake and energy expenditure levels, serum glucose
and insulin levels, and hepatic glycogen levels, indicating
that FGF21 is not to be a physiological regulator for glucose
metabolism [32].
5.Roles ofFGF21inLipolysisinAdipocytes
Mammals have evolved complex metabolic responses to
fasting. During fasting, nonesteriﬁed fatty acid (NEFA) is
released from adipocytes into the blood and taken up by
hepatocytes. Peroxisome proliferator-activated receptor α
(PPARα)i san u c l e a rr e c e p t o r .H e p a t i cFgf21 expression was
greatly induced by fasting for 24h in wild-type mice but
not PPARα knockout mice. It was also markedly induced
by a PPARα-selective agonist [23]. These results indicate
that hepatic Fgf21 expression is induced by the activation
of PPARα. NEFA binds to and activates PPARα. The ligand-
bound PPARα forms a heterodimer with RXRs and induces
the expression of Fgf21 [33]. Fasting increases the amount
of NEFA released from adipocytes. Hepatic Fgf21 expression
during fasting is probably induced through the activation
of PPARα by NEFA (Figure 2(a))[ 34, 35]. Fgf21 knockout
mice fasted for 24h showed increased lipolysis in adipocytes,J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: The evolutionary lineage of deuterostome organisms and the evolutionary history of endocrine Fgf genes. (a) The Fgf gene
family expanded in two major phases (I and II) during deuterostome evolution. Phase I occurred after the separation of protostomes and
deuterostomes. Phase II occurred early in the emergence of vertebrates. (b) Fgf13-like is the ancestral gene of the Fgf gene family. Fgf4-like
was generated from Fgf13-like by gene duplication during invertebrate evolution. Fgf15/19-like was also generated from Fgf4-like by local
gene duplication early in the emergence of vertebrates. Later, Fgf19, Fgf21, and Fgf23 were generated via two genome duplication events in
phase II.
which resulted in decreased adipocyte size and increased
serum NEFA levels [32]. These results indicate that FGF21
inhibits lipolysis in adipocytes during fasting. The regulatory
processformsanegativefeedbackloopinthecontroloflipol-
ysis by FGF21 (Figure 2(a)). FGF21 also regulates mitochon-
drial activity and enhances oxidative capacity through an
AMP-activated protein kinase- (AMPK-) sirtuin 1- (SIRT1-)
peroxisome proliferator-activated receptor-γ coactivator-1α-
(PGC-1α-) dependent mechanism in adipocytes [36].
6. Roles of FGF21 inKetogenesis and
Triglyceride Clearance in Hepatocytes
In hepatocytes, NEFA is converted to acetyl-CoA by oxi-
dation, and ketone bodies are produced from acetyl-CoA.
Ketone bodies become the predominant energy source for
the brain during fasting. Hepatic ketogenesis during fasting
was greatly impaired in PPARα knockout mice, indicating
that PPARα is crucial to the normal adaptive response
to fasting [37, 38]. As described above, hepatic Fgf21
expression is induced in response to fasting and PPARα
agonists. In addition, the phenotypes of Fgf21 transgenic
micedemonstratethatFGF21stimulateshepaticketogenesis,
indicatingthatFGF21playsaroleinhepaticketogenesis[23].
Feeding with a ketogenic diet (KD) mimics the metabolic
conditions of chronic starvation. Adenoviral knockdown of
hepatic Fgf21 i nm i c ef e dK Dc a u s e dr e d u c e db l o o dk e t o n e
levels, fatty liver, and lipemia, suggesting that FGF21 is
required for hepatic ketogenesis and triglyceride clearance
in mice fed KD [24]. In addition, serum triglyceride levels
were reduced to near normal levels in both ob/ob and
db/db mice by the administration of FGF21 [22]. These
ﬁndings also indicate functions of FGF21 in ketogenesis and
triglyceride metabolism and potential therapeutic eﬀects on
metabolic diseases [16–19]. However, hepatic ketogenesis
a n dt r i g l y c e r i d el e v e l sw e r ee s s e n t i a l l yn o r m a li nFgf21
knockout mice fasted or fed KD, indicating FGF21 not
to be a physiological regulator for hepatic ketogenesis and
triglyceride clearance in mice [32]. These results suggest
the physiological roles of FGF21 to be distinct from the
pharmacological eﬀects of FGF21 indicated by experiments
with Fgf21 transgenic mice. In humans, serum FGF21 levels
are also increased by fasting for 7 days or PPARα activation.
In contrast, ketogenesis is independent of serum FGF21
levels [39, 40]. However, it also has been reported that
Fgf21 knockout mice fed KD developed hepatosteatosis and
showed partial impairment in ketogenesis [41].
Peroxisome proliferation-activated receptor γ coactiva-
tor-1α (PGC-1α) regulates metabolism in response to
changes in nutritional status. PGC-1α negatively regulated
hepatic Fgf21 expression [42]. In contrast, FGF21 induced
hepatic Pgc-1α expression. Fgf21 knockout mice did not fully
expressPgc-1αinresponsetoprolongedfastingandexhibited4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 2: Mechanism of action and regulatory mechanism of the
gene expression of FGF21. (a) Hepatic Fgf21 expression is induced
by the activation of PPARα. NEFA binds to and activates PPARα.
The ligand-bound PPARα forms a heterodimer with RXRs and
induces the expression of Fgf21. The FGF21 inhibits lipolysis in
adipocytes. In cultured adipocytes, FGF21 signaling is transduced
by activating the βKlotho-FGFR1c complex. However, FGF21
signaling can be transduced in βKlotho knockout mice, indicating
the existence of a βKlotho-independent FGF21 signaling pathway.
The regulatory process forms a negative feedback loop in the
control of lipolysis by FGF21. (b) Feeding with a ketogenic diet
(KD) mimics the metabolic conditions of chronic starvation. KD
induces hepatic Fgf21 expression and torpor. FGF21 attenuates
torpor induced by KD.
impaired gluconeogenesis and ketogenesis. In addition,
FGF21 could not induce gluconeogenic gene expression
in Pgc-1α knockout mice [43]. These results indicate that
gluconeogenesis and ketogenesis by FGF21 are mediated in
part through PGC-1α. However, as described above, other
experiments with Fgf21 knockout mice suggest that FGF21
may not be required for gluconeogenesis and ketogenesis
[32].
7. RolesofFGF21inGrowthHormoneSignaling
inHepatocytes
Starvation inhibits growth by blocking the growth hormone
(GH)/insulin-like growth factor 1 (IGF1) signaling pathway
[44]. Fgf21 transgenic mice are 40–50% smaller than their
wild-type counterparts. Tibia length is also signiﬁcantly
reduced in Fgf21 transgenic mice. FGF21 causes resistance
to GH in the liver [45]. Actions of GH are mostly mediated
by IGF1. Igf1 expression is induced by the GH/STAT5 (signal
transducer and activator of transcription 5) signaling path-
way. The phosphorylation of STAT5 and the expression of
Igf1 are signiﬁcantly decreased in livers of Fgf21 transgenic
mice. IGF-binding protein 1 (IGFBP1), which is involved
in sequestering IGF1, inhibits IGF1 signaling. A suppressor
of cytokine signaling 2 (SOCS2) also inhibits GH signaling
by binding to the tyrosine-phosphorylated GH receptor.
The expression of Igfbp1 and Socs2 was greatly enhanced in
Fgf21 transgenic livers. These results indicate the important
role of FGF21 in the inhibition of GH/IGF1 signaling
[45]. However, Fgf21 knockout mice are apparently healthy,
and their body and tibia lengths are essentially normal
[32]. In addition, hepatic Igf1, Igfbp1,a n dSocs2 expression
was essentially normal in Fgf21 knockout mice (Murata et
al., unpublished observation). The expression of Igf1 was
slightly decreased by fasting for 24h in wild-type mice. In
contrast, the expression of Igfbp1 and Socs2 was greatly and
slightly increased in fasted wild-type mice, respectively. In
addition, the expression of Igf1, Igfbp1,a n dSocs2 in fasted
Fgf21 knockout mice was similar to that in fasted wild-
type mice (Murata et al., unpublished observation). The
Fgf21 knockout phenotypes indicate that FGF21 is not a
physiological regulator essential for GH/IGF1 signaling.
8. Roles of FGF21 in Torpor
Torpor, the controlled lowering of metabolic rates, body
temperature, and physical activity, is an adaptation that
various mammals use to cope with periods of low food
availability [46]. The basal core body temperature of Fgf21
transgenic mice is consistently lower than that of wild-
type mice. Moreover, Fgf21 transgenic mice enter torpor
on fasting for 24h, whereas wild-type mice do not [23]. In
addition, a PPAR pan-agonist reduced body temperature late
at night in concert with the induction of hepatic of Fgf21
expression [47]. However, body temperature and physical
activity were essentially normal in Fgf21 knockout mice
fasted for 24h, indicating that FGF21 is not physiologically
required for torpor induced by fasting for 24h [48]. Hepatic
Fgf21 expression and torpor were also induced in mice fed
KD for 5 days (Figure 2(b)). However, torpor was attenuated
in Fgf21 knockout mice fed KD for 5 days. These results
indicate that FGF21 is potentially involved in the torpor
induced by KD [48]( Figure 2(b)).
9. Mechanismof FGF21Action
FGF signaling is mostly mediated by the activation of FGFRs.
Four Fgfr genes, Fgfr1–Fgfr4, have been identiﬁed in humans
and mice [3, 7, 49]. These genes encode proteins (∼800
amino acids) that contain an extracellular ligand-binding
domain with three immunoglobulin-like domains (I, II, and
III), a transmembrane domain, and intracellular tyrosine
kinase domains. Fgfr1–Fgfr3 encode two major variants of
immunoglobin-like domain III (IIIb and IIIc) generated by
alternative splicing. The immunoglobulin-like domain III is
an essential determinant of ligand-binding speciﬁcity [26].
Thus, seven FGFR proteins (FGFR 1b, 1c, 2b, 2c, 3b, 3c,
and 4) with diﬀering ligand-binding speciﬁcity are generated
from Fgfr1–Fgfr4. The binding of FGFs to FGFRs induces
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activation of downstream signaling pathways: RAS-RAF-
MAPK, PI3K-AKT, STAT, and PLCγ [7, 49].
Endocrine FGFs also mediate biological responses in
an FGFR-dependent manner. However, they activate FGFRs
with very low activity even in the presence of hep-
arin/heparan sulfate, as they bind to heparin/heparan sulfate
with very low aﬃnity [25, 26]. αKlotho is a transmembrane
protein of ∼1,000 amino acids with a short cytoplasmic
domain [50]. βKlotho shares structural identity (41% amino
acid identity) and characteristics with αKlotho [51]. Fgf23
and αKlotho knockout mouse phenotypes indicate that
FGF23 and αKlotho function in a common signal trans-
duction pathway. FGF23 can bind to the αKlotho-FGFR1c
complex in cultured cells [52], suggesting that αKlotho is
a cofactor essential for FGF23 signaling. βKlotho, Fgf15/19,
and Fgfr4 knockout mouse phenotypes also indicate that
FGF15/19, FGFR4, and βKlotho function in a common
signal transduction pathway [53–55]. FGF15/19 can bind to
theβKlotho-FGFR4complexinculturedcells.FGF15/19also
activates FGF signaling in hepatocytes that primarily express
Fgfr4 [56].
In the presence of βKlotho, FGF21 can bind to and acti-
vate FGFR1c, FGFR2c, FGFR3c, or FGFR4, which activates
the MAP kinase pathway, in cultured cells, indicating that
βKlotho is also essential for FGF21 signaling in cultured
cells [57–59]. However, Fgf21 knockout mouse phenotypes
[32] are distinct from βKlotho knockout mouse phenotypes
[51]. In addition, the administration of a recombinant
human FGF21 to βKlotho knockout mice showed that
FGF21 signaling is transduced in the absence of βKlotho
[60]. These results indicate the existence of a βKlotho-
independent FGF21 signaling pathway in which undeﬁned
cofactors might be involved [60].
10.FGF21 SignalinginMetabolicDiseases
Nonalcoholic fatty liver disease (NAFLD) is a hepatic man-
ifestation of metabolic syndrome and ranges from simple
fatty liver to nonalcoholic steatohepatitis. Its prevalence
has increased dramatically over recent years in developed
countries [61]. The pathophysiological hallmark of NAFLD
is insulin resistance. NAFLD may increase the risk of type
2 diabetes and atherosclerosis [62]. Serum FGF21 levels are
signiﬁcantly increased in NAFLD (Table 1)[ 63–65]. Serum
FGF21 levels are positively correlated with intrahepatic
triglyceride levels [65]. As NAFLD is now recognized as
a major public health problem, reliable biomarkers for
NEFLD are needed. Serum FGF21 levels might be useful as
a biomarker for NEFLD [61].
Type 2 diabetes connected with visceral obesity and
insulin resistance has become a global health concern. Serum
FGF21 levels are increased in patients with type 2 diabetes,
gestational diabetes, and obesity, indicating FGF21 to be
a potential new marker in patients with type 2 diabetes
(Table 1)[ 66–71]. Serum FGF21 levels are independently
associated with markers of insulin resistance and an adverse
lipid proﬁle [66, 70]. The upregulation of serum FGF21
levels might be a compensatory mechanism to improve
Table 1:IncreasedserumFGF21levelsinmetabolicdiseasepatients
with insulin resistance.
Disease Insulin
signaling
Serum FGF21
levels
Nonalcoholic fatty liver disease Resistance Increase
Type 2 diabetes Resistance Increase
Obesity Resistance Increase
Cushing’s syndrome Resistance Increase
Lipodystrophy induced by HIV-1 Resistance Increase
Endostage renal disease Resistance Increase
glucose metabolism when insulin resistance is present. Diet-
induced obese mice also have increased serum (endogenous)
FGF21 levels and respond poorly to exogenous FGF21,
indicating that obesity is an FGF21-resistant state [72].
Impaired glucose tolerance (IGT) is an important category
of prediabetes. Serum FGF21 levels are also increased in
Chinese subjects with IGT. However, serum FGF21 levels do
not correlate with insulin resistance in the subjects [73].
Cushing’s syndrome is a hormone disorder caused by
high levels of cortisol (hypercortisolism) in the blood.
Patients with Cushing’s syndrome frequently suﬀer from
visceral obesity, insulin resistance/diabetes, and other abnor-
malities similarly to patients with metabolic syndrome.
Serum FGF21 levels are also increased in patients with
Cushing’s syndrome. The increased FGF21 levels are due
to excessive fat accumulation and related metabolic abnor-
malities rather than a direct eﬀect of cortical on FGF21
production (Table 1)[ 74].
Lipodystrophy is a common alteration in HIV-1-infected
patients under antiretroviral treatment. This syndrome is
usually associated with peripheral lipoatrophy, central adi-
posity, and, in some cases, lipomatosis, as well as systemic
insulin resistance and hyperlipidemia [75]. Serum FGF21
levels are increased in HIV-1-infected patients with lipodys-
trophy. This increase is closely associated with insulin resis-
tance, metabolic syndrome, and markers of liver damage.
FGF21 might be a biomarker of altered metabolism in HIV-
1-infected, antiretroviral-treated patients (Table 1)[ 76].
Serum FGF21 levels correlate with renal function and
are markedly increased in chronic kidney disease patients
receiving hemodialysis, suggesting a possible link between
theirFGF21levelsandrenalfunction[77].Patientswithend-
stage renal disease (ESRD) show insulin resistance. Serum
FGF21 levels are also markedly increased in patients with
ESRD, suggesting FGF21 to play a role in insulin resistance
in these patients (Table 1)[ 78].
11. Conclusion
Endocrine FGFs, FGF15/19, FGF21, and FGF23, are emerg-
ing in evolution and unique in function. The Fgf21 gene,
which was generated early in vertebrate evolution, is speciﬁc
to vertebrates. Fgf21 has been identiﬁed in most vertebrate
genomes, but not in bird genomes, indicating that it might
be lost in the bird lineage. Genome sizes and gene numbers6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
are smaller in birds than in mammalian species. As the dif-
ferences might have evolved in response to the physiological
demands of ﬂight, Fgf21 also might have been lost. FGF21
mainly acts as an endocrine factor in an FGFR-dependent
manner. FGF21 requires βKlotho as a cofactor in cultured
cells. However, it may not require βKlotho in mice. FGF21
exerts pharmacological eﬀects on hepatic glucose and lipid
metabolism and growth hormone signaling. These eﬀects
might be useful for treating metabolic diseases. However,
experiments with Fgf21 knockout mice indicated FGF21 not
to be physiologically essential for hepatic glucose and lipid
metabolism, ketogenesis, and growth hormone signaling. In
contrast, FGF21 inhibited lipolysis in adipocytes of fasted
mice and attenuated torpor induced by KD, indicating that
Fgf21 may be a “thrifty gene.” Serum FGF21 levels are
increased in patients with metabolic diseases having insulin
resistance including NAFLD, type 2 diabetes, Cushing’s
syndrome, and HIV-1-induced lipodystrophy. Although it
remains unclear whether serum FGF21 levels are increased
by FGF21 resistance or an adaptive response to metabolic
disorders, these ﬁndings indicate that FGF21 potentially
functions as a metabolic regulator in relation with insulin
resistance and is a biomarker for metabolic diseases. Further
study of FGF21 may provide clues as to its roles in lipid
metabolism and clinical treatments for metabolic diseases.
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